DCM
DAFNA Capital Management Portfolio holdings
AUM
$524M
Turnover
22.92%
1-Year Est. Return
164.42%
This Fund
S&P 500
This Quarter
Est. Return
+6.5%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$308M
AUM Growth
-$38.9M
(-11%)
Cap. Flow
-$25.7M
Cap. Flow
% of AUM
-8.35%
Top 10 Holdings %
Top 10 Hldgs %
52.97%
Holding
98
New
10
Increased
19
Reduced
20
Closed
18
Avg Time Held
2.1
years
Top 10 Avg Time Held
0.9
years
Top 20 Avg Time Held
1.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
IDEAYA Biosciences
IDYA
|
+$4.11M |
| 2 |
Arcturus Therapeutics
ARCT
|
+$4M |
| 3 |
Translate Bio, Inc. Common Stock
TBIO
|
+$2.94M |
| 4 |
89bio
ETNB
|
+$2.85M |
| 5 |
Ascendis Pharma A/S
ASND
|
+$2.16M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$11.3M |
| 2 |
Kura Oncology
KURA
|
+$5.64M |
| 3 |
Syndax Pharmaceuticals
SNDX
|
+$3.92M |
| 4 |
Compugen
CGEN
|
+$3.73M |
| 5 |
Akebia Therapeutics
AKBA
|
+$3.69M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.07% |
| 2 | Miscellaneous | 3.93% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Stereotaxis
STXS
$105M
| $49M | 15.92% |
13,680,554
| – | – |
2013 Q2
29 quarters
|
|
|
IMMU
2
DELISTED
Immunomedics Inc
IMMU
| $22.2M | 7.21% |
260,905
+10,000
| +4% | +$506K |
2020 Q2
1 quarter
|
|
3
DELISTED
Blueprint Medicines
BPMC
| $21.6M | 7.02% |
233,089
+5,000
| +2% | +$385K |
2016 Q4
15 quarters
|
|
4
Fate Therapeutics
FATE
$232M
| $17.5M | 5.7% |
438,460
-52,401
| -11% | -$1.83M |
2019 Q2
5 quarters
|
|
|
5
Arcturus Therapeutics
ARCT
$316M
| $9.85M | 3.2% |
229,652
+80,635
| +54% | +$4M |
2018 Q4
7 quarters
|
|
6
DELISTED
Sage Therapeutics
SAGE
| $9.68M | 3.15% |
158,306
-7,000
| -4% | -$355K |
2017 Q4
11 quarters
|
|
7
DexCom
DXCM
$31.5B
| $8.71M | 2.83% |
84,552
| – | – |
2017 Q3
12 quarters
|
|
8
Neurocrine Biosciences
NBIX
$13.8B
| $8.67M | 2.82% |
90,208
+17,000
| +23% | +$1.97M |
2016 Q1
18 quarters
|
|
|
DRNA
9
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $8.17M | 2.66% |
454,236
| – | – |
2018 Q2
9 quarters
|
|
10
iShares Biotechnology ETF
IBB
$10.4B
| $7.57M | 2.46% |
55,900
+1,000
| +2% | +$136K |
2016 Q4
15 quarters
|
|
11
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.93B
| $6.3M | 2.05% |
44,375
| – | – |
2015 Q3
20 quarters
|
|
|
CSII
12
DELISTED
Cardiovascular Systems, Inc.
CSII
| $5.95M | 1.93% |
151,200
| – | – |
2018 Q2
9 quarters
|
|
13
ProQR Therapeutics
PRQR
$207M
| $5.93M | 1.93% |
1,237,400
| – | – |
2017 Q4
11 quarters
|
|
|
ARNA
14
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $5.67M | 1.84% |
75,815
-169,327
| -69% | -$11.3M |
2018 Q1
10 quarters
|
|
15
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $5.5M | 1.79% |
84,600
-3,000
| -3% | -$197K |
2018 Q2
9 quarters
|
|
|
AGTC
16
DELISTED
Applied Genetic Technologies Corporation
AGTC
| $5.32M | 1.73% |
1,095,139
-65,739
| -6% | -$359K |
2015 Q1
22 quarters
|
|
17
AtriCure
ATRC
$2.91B
| $5.32M | 1.73% |
133,229
| – | – |
2013 Q2
29 quarters
|
|
|
18
Ascendis Pharma A/S
ASND
$14.9B
| $4.51M | 1.47% |
29,237
+15,000
| +105% | +$2.16M |
2015 Q1
22 quarters
|
|
|
19
IDEAYA Biosciences
IDYA
$3.27B
| $4.17M | 1.35% |
+331,661
| New | +$4.11M |
2020 Q3
0 quarters
|
|
|
LMNX
20
DELISTED
Luminex Corp
LMNX
| $4.04M | 1.31% |
154,091
| – | – |
2017 Q3
12 quarters
|
|
21
Xenon Pharmaceuticals
XENE
$3.28B
| $3.84M | 1.25% |
346,535
| – | – |
2015 Q3
20 quarters
|
|
|
CNST
22
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $3.67M | 1.19% |
180,942
+10,000
| +6% | +$244K |
2020 Q2
1 quarter
|
|
|
AERI
23
DELISTED
Aerie Pharmaceuticals
AERI
| $3.35M | 1.09% |
284,440
+5,000
| +2% | +$60.9K |
2014 Q3
24 quarters
|
|
24
Tvardi Therapeutics
TVRD
$13.3M
| $3.15M | 1.02% |
6,872
-3,434
| -33% | -$1.99M |
2017 Q3
12 quarters
|
|
25
DELISTED
Affimed
AFMD
| $3.13M | 1.02% |
92,428
+7,928
| +9% | +$300K |
2019 Q4
3 quarters
|
|
Similar funds
4WM
BB
A
HW
DAM
SDWIA
SCA
BHPW
DAFNA Capital Management's Q3 2020 Portfolio in Review
As of Q3 2020, DAFNA Capital Management held 98 positions worth $308M, down 11% from $347M the previous quarter. Its ten largest holdings account for 53% of the portfolio.
DAFNA Capital Management withdrew a net $25.7M in Q3 2020, closing 18 positions and reducing 20 holdings. Its most notable exit was Mirati Therapeutics, Inc. Common Stock, an estimated $2.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, DAFNA Capital Management opened a new position in IDEAYA Biosciences worth $4.17M.
- DAFNA Capital Management's largest Q3 2020 buy was IDEAYA Biosciences: 331,661 shares worth $4.17M.
- DAFNA Capital Management added most to Arcturus Therapeutics in Q3 2020, an estimated $4M increase.
- DAFNA Capital Management's biggest Q3 2020 reduction was Arena Pharmaceuticals Inc, cutting an estimated $11.3M.
- DAFNA Capital Management fully exited Mirati Therapeutics, Inc. Common Stock in Q3 2020, selling an estimated $2.5M.
- DAFNA Capital Management's ten largest holdings make up 53% of its $308M portfolio in Q3 2020.
- DAFNA Capital Management opened 10 new positions and closed 18 in Q3 2020.
- DAFNA Capital Management's portfolio value fell 11% quarter-over-quarter to $308M.
Based on DAFNA Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.